W
bioLLM/wiki

AI-Curated Biotech/Medical Knowledge Base
Live
Back to List View Graph View

Aflibercept

Aflibercept is a therapeutic biologic used primarily as an anti-angiogenic agent.

Where the papers sit

9 papers from the last 6 months study aflibercept directly · updated from PubMed 10 Oct 2026

Study type 1 clinical trial · 3 observational · 1 human data · 1 preclinical · 3 unclassified

Themes one subject · 1 new direction

Those 9 are all about one subject.

  • Anti-VEGF Therapeutic Use

    Anti-VEGF treatment is being refined through safer dosing, longer drug exposure, biosimilar substitution and real-world comparisons. In neovascular AMD, aflibercept 8 mg and switching from faricimab are associated with anatomical rescue, while hemorrhage risk remains a key endpoint. Population pharmacokinetics and sustained-release hydrogels aim to reduce injection burden. Applications also extend to diabetic macular oedema and selected frail patients with metastatic colorectal cancer.

    9 papers

NEW DIRECTION

Aflibercept is used as a systemic first-line angiogenesis inhibitor in frail or older adults with metastatic colorectal cancer

The AIO/IKF ELDERLY trial studied older or frail patients with metastatic colorectal cancer, comparing aflibercept plus 5-fluorouracil with FOLFOX as first-line treatment. Whereas the other papers use aflibercept primarily as an intravitreal anti-VEGF treatment for retinal disease, this trial assigns it a role in systemic oncology alongside chemotherapy. This extends aflibercept beyond the ophthalmic treatment framework represented by the rest of the set 41905242Mar.

Papers

The 9 papers from the last 6 months that study aflibercept directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

Anti-VEGF Therapeutic Use (9)
  1. PMID 41905242
  2. Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents. PloS one · 27 Aug 2026 PMID 42658802
  3. Early anatomical rescue after switching to aflibercept 8 mg in faricimab-refractory neovascular AMD. International ophthalmology · 26 Aug 2026 PMID 42642671
  4. Real-world safety of aflibercept 8 mg in neovascular age-related macular degeneration. Naunyn-Schmiedeberg's archives of pharmacology · 10 Aug 2026 PMID 42576020
  5. Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2 Jul 2026 PMID 42390573
  6. Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products. CPT: pharmacometrics & systems pharmacology · 1 Jul 2026 PMID 42381356
  7. Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. BMJ open ophthalmology · 29 Jun 2026 PMID 42373197
  8. Visible Light Photo-Cross-Linked Thermogel─A Single-Component Hybrid Supramolecular-Covalent Hydrogel for Sustained Drug Release. ACS applied materials & interfaces · 14 May 2026 PMID 42131985
  9. Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data. PloS one · 7 May 2026 PMID 42096458

By study type

Clinical trials (1)
  1. Safety and efficacy of biosimilar aflibercept MYL-1701P in diabetic macular oedema: 20-week extension results following the INSIGHT pivotal trial. BMJ open ophthalmology · 29 Jun 2026 PMID 42373197
Observational studies and case reports (3)
  1. Risk of intraocular hemorrhage among exudative age-related macular degeneration patients treated with different anti-VEGF agents. PloS one · 27 Aug 2026 PMID 42658802
  2. Early anatomical rescue after switching to aflibercept 8 mg in faricimab-refractory neovascular AMD. International ophthalmology · 26 Aug 2026 PMID 42642671
  3. Nationwide trends and regional variation in intravitreal injections and anti-VEGF agent use in Japan from 2017 to 2022: An analysis of the NDB Open Data. PloS one · 7 May 2026 PMID 42096458
Human data, design not indexed (1)
  1. Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products. CPT: pharmacometrics & systems pharmacology · 1 Jul 2026 PMID 42381356
Preclinical: animal, cell and lab studies (1)
  1. Visible Light Photo-Cross-Linked Thermogel─A Single-Component Hybrid Supramolecular-Covalent Hydrogel for Sustained Drug Release. ACS applied materials & interfaces · 14 May 2026 PMID 42131985
Unclassified: not yet indexed with MeSH (3)
  1. Early Real-World Outcomes of Intravitreal Aflibercept 8 mg for Neovascular Age-Related Macular Degeneration in France: A Retrospective Study. Ophthalmology and therapy · 5 Oct 2026 PMID 42832168
  2. Real-world safety of aflibercept 8 mg in neovascular age-related macular degeneration. Naunyn-Schmiedeberg's archives of pharmacology · 10 Aug 2026 PMID 42576020
  3. Real-world comparison of faricimab and aflibercept as second-line therapies for neovascular age-related macular degeneration. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie · 2 Jul 2026 PMID 42390573
bioLLM/wiki is a literature-navigation aid for people who read primary research. It is not a medical resource, and it is not a substitute for a clinician, a pharmacist or the source papers themselves. Because the articles are drafted by language models, they can be incomplete or wrong in ways that read fluently. Please see the editorial policy and medical disclaimer before relying on anything here.

Written from 9 PubMed abstracts, each one listed by PMID above. Published: 2026-07-03. Last written: 2026-08-29 by GPT. Drafted by language models from published abstracts; not medical advice.